Who Shall and Shall Not Have a Place in the World?
By Lily Hu,
Los Angeles Review of Books
| 02. 13. 2025
IN MAY 1921, the organizers of the Second International Congress of Eugenics assured the public that its conference, to be held later that year in September, would be taking a measured approach to “the topic of human racial differences.” All sides of the matter would be soberly considered; no conclusions would be reached in a hurry. The public could feel secure that, as the statement brightly declared, “certain prejudices directed toward existing races will be removed when allowance is made for the influence of their social and educational environment, and their fundamentally sound and strong racial characteristics are brought to light. On the other hand,” the announcement more somberly continued, “limits to development of certain races and the inalterability through education and environment of the fundamental characteristics of certain stocks will be considered.”
By the time the first meeting of the congress rolled around, a scant five months later, the science seemed to have been settled—and it apparently gave reason for considerable alarm. In his welcome address, Henry Fairfield Osborn, president of the American Museum of Natural History and soon-to-be...
Related Articles
By Matt Novak, Gizmodo | 07.23.2025
Robert F. Kennedy Jr., the Secretary of Health and Human Services, has made a big push to get agencies like the Food and Drug Administration to use generative artificial intelligence tools. In fact, Kennedy recently told Tucker Carlson that AI...
By Keith Casebonne and Jodi Beckstine [with CGS' Katie Hasson], Disability Deep Dive | 07.24.2025
In this episode of Disability Deep Dive, hosts Keith and Jodi explore the complex interplay between disability science, technology, and ethics with guest Katie Hasson, Associate Director at the Center for Genetics and Society. The conversation delves into...
By Angus Liu, Fierce Pharma | 07.22.2025
A brief skirmish between Sarepta Therapeutics and the FDA has ended before escalating into a full-on regulatory clash, as the company has bowed to the agency’s demand.
In a surprising reversal, Sarepta on Monday said it will pause all shipments...
By Lucy Tu, The Atlantic | 07.11.2025
Donald Trump—who is, by his own accounting, “the fertilization president” and “the father of IVF”—wants to help Americans reproduce. During his 2024 campaign, he promised that the government or insurance companies would cover the cost of in vitro fertilization. In...